Skip to main content
Premium Trial:

Request an Annual Quote

James Burns, J. Stark Thompson


James Burns, president and CEO of the clinical-stage pharmaceutical company EntreMed, has joined Ciphergen's board of directors, Ciphergen announced last week.

Burns joined EntreMed in June 2004. Prior to that, he was the co-founder of MedPointe, where he served as president and executive vice president. From 2000 to 2001, Burns served as founder and managing director of MedPointe Captial Partners. From 1993 to 1999, Burns was the founder, chairman, president and CEO of the biotechnology company Osiris Therapeutics. From 1986 to 1992, he was vice chairman of Health Care Investment, and a founding general partner of Healthcare Ventures, a venture capital partnership that specialized in forming companies built around new pharmaceutical and biotechnology products. From 1981 to 1986, Burns served as group president and vice president of the laboratory products group at Becton Dickinson.

Burns is the chairman of the executive committee of the International BioResources Group and the American Type Culture Collection, and a trustee of the University of Maryland Biotechnology Institute. He earned his BS and MS degrees in biological sciences from the University of Illinois. In addition, he received an MBA degree from DePaul University.

Luminex this week announced the appointment of J. Stark Thompson to the board of directors, where he will serve as a class III director. Most recently, Thompson served as president, CEO, and director of Life Technologies. Thompson has a BS from Muskingum College and an MS and PhD in Physiological Chemistry from Ohio State University. He currently serves as chair of the board of directors of Gene Logic, as well as serving as a director in various other private and civic organizations.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.